| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Purity: ≥98%
PF-3644022 (PF3644022) is a novel, potent, selective, orally bioactive, and ATP-competitive inhibitor of mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) with anticancer activity. It inhibits MAPK2-MK2 with an IC50 of 5.2 nM and a Ki of 3 nM. PF-3644022 inhibits tumor necrosis factor α (TNFα) production in U937 monocytic cells and peripheral blood mononuclear cells (PBMCs) (IC50 = 160 nM).
| ln Vitro |
It was determined whether PF-3644022 inhibited the activity of other MAPKAP kinase family members. Other members of the family are at least hundreds of times more selective than MK2, and are essentially not inhibited, with the exception of MNK2, which has an IC50 of 148 nM [1]. With an IC50 of 160 nM, PF-3644022 effectively suppresses TNFα production in peripheral blood mononuclear cells or the human U937 mononuclear cell line. PF-3644022 inhibits the production of TNFα and IL-6 in human whole blood when stimulated by LPS, with IC50 values of 1.6 and 10.3 μM, respectively. Phosphoheat shock protein 27, a target biomarker of MK2 activity, is tightly correlated with the suppression of TNFα in U937 cells and blood [1].
|
|---|---|
| ln Vivo |
Treatment with PF-3644022 (3-100 mg/kg; oral gavage; twice daily; for 12 days; Lewis rats) showed dose-dependent inhibition of chronic paw swelling measured on day 21 after 12 days of oral dosing, ED50 values is 20 mg/kg[1].
|
| Animal Protocol |
Animal/Disease Models: Female Lewis rats (125-140 g) were injected with Streptococcus cell wall [1]
Doses: 3 mg/kg, 10 mg/kg, 30 mg/kg, 50 mg/kg, 100 mg/kg Route of Administration: po (oral gavage); twice (two times) daily; for 12 days Experimental Results: Demonstrated dose-dependent inhibition of chronic paw swelling as measured on day 21 after 12 days of oral administration. |
| References |
| Molecular Formula |
C21H18N4OS
|
|---|---|
| Molecular Weight |
374.46
|
| Exact Mass |
374.12
|
| CAS # |
1276121-88-0
|
| Related CAS # |
1276121-88-0;
|
| PubChem CID |
44631903
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.512
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
27
|
| Complexity |
574
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@@H]1CNC2=C(C(=O)N1)SC3=C2C4=C(C=C3)N=C(C=C4)C5=CN=C(C=C5)C
|
| InChi Key |
CMWRPDHVGMHLSZ-GFCCVEGCSA-N
|
| InChi Code |
InChI=1S/C21H18N4OS/c1-11-3-4-13(10-22-11)15-6-5-14-16(25-15)7-8-17-18(14)19-20(27-17)21(26)24-12(2)9-23-19/h3-8,10,12,23H,9H2,1-2H3,(H,24,26)/t12-/m1/s1
|
| Chemical Name |
(15R)-15-methyl-5-(6-methylpyridin-3-yl)-11-thia-6,14,17-triazatetracyclo[8.8.0.0^{2,7}.0^{12,18}]octadeca-1(10),2,4,6,8,12(18)-hexaen-13-one
|
| Synonyms |
PF3644022 PF 3644022 PF-3644022.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~41.67 mg/mL (~111.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (5.55 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6705 mL | 13.3526 mL | 26.7051 mL | |
| 5 mM | 0.5341 mL | 2.6705 mL | 5.3410 mL | |
| 10 mM | 0.2671 mL | 1.3353 mL | 2.6705 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA